ストックスクリーナーアプリを入手
2.07
3.50%
0.07
アフターアワーズ：
2.10
0.03
+1.45%
前日終値:
$2.00
開ける：
$1.98
24時間の取引高:
459.93K
Relative Volume:
0.41
時価総額：
$100.05M
収益：
-
当期純損益:
$-123.46M
株価収益率:
-0.7964
EPS:
-2.5993
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
+2.99%
1か月 パフォーマンス:
-5.91%
6か月 パフォーマンス:
-36.31%
1年 パフォーマンス:
+11.89%
1日の値動き範囲:
$1.95
$2.095
1週間の範囲:
$1.92
$2.15
52週間の値動き範囲:
$1.14
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake - Yahoo Finance UK
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update - MarketBeat
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025 - Insider Monkey
You might want to take a look at BioAtla Inc (BCAB) now - SETE News
BioAtla Inc (BCAB) stock: A year of ups and downs - US Post News
Market Insights: BioAtla Inc (BCAB)’s Notable Gain of 7.25, Closing at 2.07 - The Dwinnex
636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC - Defense World
AQR Capital Management LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - SETE News
Bank of Montreal Can Buys 143,521 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
Renaissance Technologies LLC Sells 370,800 Shares of BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) - Seeking Alpha
Analyzing the Impact of Earnings Reports on BioAtla Inc Inc. (BCAB) Price Performance - The InvestChronicle
BioAtla to Score Up to $133M - San Diego Business Journal
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 - Quantisnow
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com
Pleasing Signs As A Number Of Insiders Buy BioAtla Stock - Simply Wall St
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
JMP Securities gives a Mkt outperform recommendation for BioAtla Inc (BCAB) - Knox Daily
Rhumbline Advisers Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Potential Price Increase for Equinix Inc (EQIX) After Recent Insider Activity - Knox Daily
BCAB’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Analyzing BCAB’s price-to-book ratio for the last quarter - US Post News
Michael Burry buys 634,000 shares of this $1 penny stockFinbold - Finbold - Finance in Bold
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress - The Manila Times
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
A new trading data show BioAtla Inc (BCAB) is showing positive returns. - SETE News
XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Michael Burry just bought 633,959 shares in this $1 penny stock - Motley Fool UK
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Wall Street SWOT: BioAtla stockInnovative cancer therapy faces pivotal year - Investing.com
BCAB’s valuation metrics: A comprehensive analysis - US Post News
Scion Asset Management LLC Purchases New Holdings in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla - The Pharma Letter
Analyzing Bio-Techne Corp (TECH) After Recent Trading Activity - Knox Daily
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 33,209 Shares - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
(BTMD) Technical Pivots with Risk Controls - Stock Traders Daily
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Dawson James downgrades BioCardia Inc. (BCDA) stock to a Neutral - Knox Daily
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Sells $245,706.93 in Stock - Defense World
SickKids names FCB Canada new AOR - Strategy Online
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset - Fierce Biotech
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
Bioatla Inc (BCAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SHORT JAY M PHD | Chief Executive Officer |
Dec 20 '23 |
Buy |
2.14 |
50,000 |
106,910 |
1,439,283 |
| STEINMAN LAWRENCE | Director |
Dec 19 '23 |
Buy |
2.05 |
20,000 |
41,048 |
38,459 |
| Vasquez Christian | See Remarks |
Dec 19 '23 |
Buy |
2.04 |
7,495 |
15,262 |
115,659 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):